Treatment of myelodysplastic syndrome with 2 schedules and doses of oral topotecan: A randomized phase 2 trial by the Cancer and Leukemia Group B (CALGB 19803)

Cancer

Volumn 115, Issue 1, 2009, Pages 84-93

  Grinblatt, David L ^a   Yu, Daohai ^b   Hars, Vera ^c   Vardiman, James W ^d   Powell, Bayard L ^e   Nattam, Sreenivasa ^f   Silverman, Lewis R ^g   De Castro III, Carlos ^h   Stone, Richard M ⁱ   Bloomfield, Clara D ^j   Larson, Richard A ^d  

^a NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

^e WAKE FOREST SCHOOL OF MEDICINE   (United States)

^f Fort Wayne Oncology and Hematology Inc   (United States)

^g MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^h DUKE UNIVERSITY   (United States)

ⁱ DANA FARBER CANCER INSTITUTE   (United States)

^j OHIO STATE UNIVERSITY   (United States)

more..

Author keywords

Chronic myelomonocytic leukemia; Cytogenetic risk group; French American British classification; International prognostic scoring system; Pharmacokinetics; Refractory cytopenia; Topoisomerase I inhibitor; Toxicity

Indexed keywords

TOPOTECAN;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ARTICLE; BLEEDING; CANCER SURVIVAL; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOGENETICS; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DYSPNEA; ERYTHROCYTE TRANSFUSION; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HUMAN CELL; INFECTION; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; NEUTROPHIL COUNT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REFRACTORY ANEMIA; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT RESPONSE; DOSE RESPONSE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; EPISTAXIS; PHASE 2 CLINICAL TRIAL; TREATMENT DURATION;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; TOPOTECAN;

EID: 58949094409     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23995     Document Type: Article

References (27)

1. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51:189-199.
2. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100:2292-2302.
3. Mufti GJ, Steven JR, Oscier DG, Hamblin TJ, Machin D. Myelodysplastic syndromes: a scoring system with prognostic significance. Br J Haematol. 1985;59:425-433.
4. Piedras J, Hernandez G, Lopez-Karpovitch X. Effect of androgen therapy and anemia on serum erythropoietin levels in patients with aplastic anemia and myelodysplastic syndrome [abstract 1341]. Blood. 1995;86:338a.
5. Negrin RS, Haeuber DH, Nagler A, et al. Treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor. A phase I-II trial. Ann Intern Med. 1989;110:976-984.
6. Vadhan-Raj S, Keeting M, LeMaistre A, et al. Effects of recombinant human granulocyte-macrophage colony stimulating factor in patients with myelodysplastic syndromes. N Engl J Med. 1987;317:1545-1552.
7. Koeffler HP, Heitjan D, Mertelsmann R, et al. Randomized study of 13-cis retinoic acid versus placebo in the myelodysplastic disorders. Blood. 1988;71:703-708.
8. Zorat F, Shetty V, Dutt D, et al. The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes. Br J Haematol. 2001;115:881-894.
9. List AF, Brasfield F, Heaton R, et al. Stimulation of hematopoiesis by amifostine in patients with myelodysplastic syndrome. Blood. 1997;90:3364-3369.
10. Fenaux P, Raza A, Mufti GJ, et al. A multicenter phase 2 study of the farnesyl transferase inhibitor tipifarnib in intermediate-to high-risk myelodysplastic syndrome. Blood. 2007;109:4158-4163.
11. Raza A, Buonamici S, Lisak L, et al. Arsenic trioxide and thalidomide combination produces multilineage hematological responses in myelodysplastic syndromes patients, particularly in those with high pretherapy EVI1 expression. Leuk Res. 2004;28:791-803.
12. Hellstrom-Lindberg E, Gulbrandsen N, Lindberg G, et al; Scandinavian MDS Group. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol. 2003;120:1037-1046.
13. Miller KB, Kim K, Morrison FS, et al. The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: a phase III intergroup study. Ann Hematol. 1992;65:162-168.
14. Silverman LR, Demakos EP, Peterson BL, et al. A randomized controlled trial of azacytidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. J Clin Oncol. 2002;20:2429-2440.
15. Silverman LR, McKenzie DR, Peterson BL, Backstrom JT, Beach CL, Larson RA. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921 and 9221 by the Cancer and Leukemia Group B. J Clin Oncol. 2006;24:3895-3903.
16. Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006;106:1794-1803.
17. List A, Dewald G, Bennett J, et al; Myelodysplastic Syndrome-003 Study Investigators. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006;355:1456-1465.
18. Raza A, Reeves JA, Feldman EJ, et al. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood. 2008;111:86-93.
19. Kornblith AB, Herndon JE 2nd, Silverman LR, et al. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. J Clin Oncol. 2002;20:2441-2452.
20. Beran M, Kantarjian H, O'Brien S, et al. Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood. 1996;88:2473-2479.
21. Rowinsky EK, Grochow L, Hendricks C, et al. Phase I and pharmacologic study of topotecan: a novel topoisomerase-1 inhibitor. J Clin Oncol. 1992;10:647-656.
22. Rowinsky EK, Adjei A, Ross C, et al. Phase I and pharmacologic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia. J Clin Oncol. 1994;12:2193-2203.
23. Kantarjian HM, Beran M, Ellis A, et al. Phase I study of topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia. Blood. 1993;81:1146-1151.
24. Beran M, Kantarjian H. Results of topotecan-based combination therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia. Semin Hematol. 1999;36(suppl 8):3-10.
25. Larson RA. Myelodysplasia: when to treat and how? Best Pract Res Clin Haematol. 2006;19:293-300.
26. Klein CE, Kastrissios H, Miller AA, et al. Pharmacokinetics, pharmacodynamics and adherence to oral topotecan in myelodysplastic syndromes: a Cancer and Leukemia Group B study. Cancer Chemother Pharmacol. 2006;57:199-206.
27. Gerrits CJH, Burris H, Schellens JHM, et al. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors. Clin Cancer Res. 1998;4:1153-1158.